PharmaCorp Rx Inc.
PCRX.V
TSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 58.20% | 9.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 58.20% | 9.74% | |||
| Cost of Revenue | 64.10% | 7.89% | |||
| Gross Profit | 49.62% | 12.55% | |||
| SG&A Expenses | 44.14% | 18.78% | |||
| Depreciation & Amortization | 51.92% | 18.42% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 55.17% | 12.67% | |||
| Operating Income | -26.04% | -51.55% | |||
| Income Before Tax | -25.10% | -88.82% | |||
| Income Tax Expenses | 1,877.37% | -112.00% | |||
| Earnings from Continuing Operations | -112.82% | -6.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -63.16% | -1,208.33% | |||
| Net Income | -110.70% | -11.82% | |||
| EBIT | -26.04% | -51.55% | |||
| EBITDA | 26.60% | -84.36% | |||
| EPS Basic | -69.23% | -8.33% | |||
| Normalized Basic EPS | 0.00% | -100.00% | |||
| EPS Diluted | -69.23% | -8.33% | |||
| Normalized Diluted EPS | 0.00% | -100.00% | |||
| Average Basic Shares Outstanding | 26.75% | 0.00% | |||
| Average Diluted Shares Outstanding | 26.75% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||